Sana Biotechnology, Inc. Variable Lease, Cost
Sana Biotechnology, Inc. (SANA) reported Variable Lease, Cost of $2.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-10
- Sana Biotechnology, Inc. variable lease, cost for the quarter ending 2026-06-30 was $2.23M, a 2.67% increase year-over-year.
- Sana Biotechnology, Inc. variable lease, cost for the quarter ending 2026-03-31 was $2.15M, a 17.69% increase year-over-year.
- Sana Biotechnology, Inc. variable lease, cost for the quarter ending 2025-12-31 was $2.20M, a 0.18% decline year-over-year.
- Sana Biotechnology, Inc. variable lease, cost for the quarter ending 2025-09-30 was $2.24M, a 2.19% increase year-over-year.
- Sana Biotechnology, Inc. variable lease, cost for fiscal 2025 was $8.44M, a 0.74% decline from fiscal 2024.
- Sana Biotechnology, Inc. variable lease, cost for fiscal 2024 was $8.51M, a 12.99% increase from fiscal 2023.
- Sana Biotechnology, Inc. variable lease, cost for fiscal 2023 was $7.53M, a 4.64% increase from fiscal 2022.
- Sana Biotechnology, Inc. variable lease, cost for fiscal 2022 was $7.19M, a 37.53% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.23M 10-Q · filed 2026-08-10 | $4.38M 10-Q · filed 2026-08-10 | $6.58M derived: sum of 3 quarters · filed 2026-08-10 | $8.82M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $2.15M 10-Q · filed 2026-05-11 | $4.35M derived: sum of 2 quarters · filed 2026-05-11 | $6.60M derived: sum of 3 quarters · filed 2026-05-11 | $8.77M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $4.45M derived: sum of 2 quarters · filed 2026-03-03 | $6.62M derived: sum of 3 quarters · filed 2026-08-10 | $8.44M 10-K · filed 2026-03-03 |
| 2025-09-30 | $2.24M 10-Q · filed 2025-11-06 | $4.41M derived: sum of 2 quarters · filed 2026-08-10 | $6.24M 10-Q · filed 2025-11-06 | $8.45M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $2.17M 10-Q · filed 2026-08-10 | $4.00M 10-Q · filed 2026-08-10 | $6.20M derived: sum of 3 quarters · filed 2026-08-10 | $8.40M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $1.83M 10-Q · filed 2026-05-11 | $4.03M derived: sum of 2 quarters · filed 2026-05-11 | $6.23M derived: sum of 3 quarters · filed 2026-05-11 | $8.32M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $4.40M derived: sum of 2 quarters · filed 2026-03-03 | $6.49M derived: sum of 3 quarters · filed 2026-03-03 | $8.51M 10-K · filed 2026-03-03 |
| 2024-09-30 | $2.19M 10-Q · filed 2025-11-06 | $4.28M derived: sum of 2 quarters · filed 2025-11-06 | $6.30M 10-Q · filed 2025-11-06 | $8.02M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $2.09M 10-Q · filed 2025-08-11 | $4.10M 10-Q · filed 2025-08-11 | $5.83M derived: sum of 3 quarters · filed 2026-03-03 | $7.72M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $2.01M 10-Q · filed 2025-05-08 | $3.74M derived: sum of 2 quarters · filed 2026-03-03 | $5.63M derived: sum of 3 quarters · filed 2026-03-03 | $7.56M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $3.62M derived: sum of 2 quarters · filed 2026-03-03 | $5.54M derived: sum of 3 quarters · filed 2026-03-03 | $7.53M 10-K · filed 2026-03-03 |
| 2023-09-30 | $1.89M 10-Q · filed 2024-11-08 | $3.82M derived: sum of 2 quarters · filed 2024-11-08 | $5.80M 10-Q · filed 2024-11-08 | $7.77M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $1.93M 10-Q · filed 2024-08-08 | $3.91M 10-Q · filed 2024-08-08 | $5.88M derived: sum of 3 quarters · filed 2025-03-17 | $7.71M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $1.98M 10-Q · filed 2024-05-08 | $3.95M derived: sum of 2 quarters · filed 2025-03-17 | $5.78M derived: sum of 3 quarters · filed 2025-03-17 | $7.69M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $3.80M derived: sum of 2 quarters · filed 2025-03-17 | $5.70M derived: sum of 3 quarters · filed 2025-03-17 | $7.19M 10-K · filed 2025-03-17 |
| 2022-09-30 | $1.83M 10-Q · filed 2023-11-08 | $3.73M derived: sum of 2 quarters · filed 2023-11-08 | $5.22M 10-Q · filed 2023-11-08 | $6.44M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $1.90M 10-Q · filed 2023-08-03 | $3.39M 10-Q · filed 2023-08-03 | $4.61M derived: sum of 3 quarters · filed 2024-02-29 | $5.89M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $1.49M 10-Q · filed 2023-05-08 | $2.70M derived: sum of 2 quarters · filed 2024-02-29 | $3.99M derived: sum of 3 quarters · filed 2024-02-29 | $5.63M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $2.50M derived: sum of 2 quarters · filed 2024-02-29 | $4.14M derived: sum of 3 quarters · filed 2024-02-29 | $5.23M 10-K · filed 2024-02-29 |
| 2021-09-30 | $1.29M 10-Q · filed 2022-11-02 | $2.93M derived: sum of 2 quarters · filed 2022-11-02 | $4.01M 10-Q · filed 2022-11-02 | $4.79M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $1.64M 10-Q · filed 2022-08-04 | $2.73M 10-Q · filed 2022-08-04 | $3.50M derived: sum of 3 quarters · filed 2023-03-16 | $4.34M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $1.09M 10-Q · filed 2022-05-10 | $1.86M derived: sum of 2 quarters · filed 2023-03-16 | $2.70M derived: sum of 3 quarters · filed 2023-03-16 | $3.55M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $775.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $1.61M derived: sum of 2 quarters · filed 2023-03-16 | $2.46M derived: sum of 3 quarters · filed 2023-03-16 | $3.08M 10-K · filed 2023-03-16 |
| 2020-09-30 | $837.00K 10-Q · filed 2021-11-08 | $1.69M derived: sum of 2 quarters · filed 2021-11-08 | $2.31M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $848.00K 10-Q · filed 2021-08-04 | $1.47M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $621.00K 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $1.49M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |